Elements inspired by the principles of value-based insurance design (VBID) were incorporated into the recently signed Inflation Reduction Act, which could help reduce costs of care for patients, according to A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.
Elements inspired by the principles of value-based insurance design (VBID) were incorporated into the recently signed Inflation Reduction Act (IRA), which could help reduce costs of care for patients, according to A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.
Transcript
How is the IRA implementing some VBID elements to reduce out-of-pocket costs for essential medical services?
We were very excited to see that the Inflation Reduction Act of 2022 includes several value-based insurance design, or VBID, related elements. Notably, first, it caps Medicare patients’ out-of-pocket costs at $2000 per year, with an option to break that amount into affordable monthly payments. Second, it covers adult vaccines recommended by the Advisory Committee on Immunization Practices at the CDC, under Medicare Part D without cost sharing. Third is amendment of the Internal Revenue Service code to create a safe harbor allowing health savings account qualified health plans to cover insulin prior to meeting the plan deductible, and most notably and covered widespread by the media, the cap on Medicare patients’ out-of-pocket costs for insulin at $35 per month.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More